The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-20 and is reviewed periodically as new material appears.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
West Yorkshire contains green belt interspersed throughout the county, surrounding the West Yorkshire Urban Area. It was first drawn up in the 1950s. All the county's districts contain large portions of green belt.
=== Stability === Thionyl chloride has a long shelf life, however "aged" samples develop a yellow hue, possibly due to the formation of disulfur dichloride. It slowly decomposes to S2Cl2, SO2 and Cl2 at just above the boiling point. Thionyl chloride is susceptible to photolysis, which primarily proceeds via a radical mechanism. Samples showing signs of ageing can be purified by distillation under reduced pressure, to give a colourless liquid.
The enthalpy of sublimation, measured through testing of fermium alloys, is calculated at 33.8±3 kcal/mol (141.4±12.6 kJ/mol) derived from Second Law values, and 34.8 kcal/mol (145.6 kJ/mol) derived from Third Law values, both at 298 K. Through this, fermium is considered a divalent metal.
The giant gourami is also popular in aquaria. Tanks commonly have dark bottoms, with densely planted edges, and room left in the center of the tank for them to swim. They prefer the company of other fish of similar sizes and temperament. They are easy to keep at three months old at around 7.5 cm (3 in long). At this age, they have a pronounced beak. They can grow rapidly given sufficient food and space to move. Even under less than ideal conditions, gourami can grow from 7.5 cm (3 in) to 50 cm (19 in) four years. At this age, in addition to the rounded face, a mature giant gourami will have begun to develop the hump just above its eyes. Taiwanese and Malaysians admired fish with protruding heads, known as 'kaloi' or 'warships', found in the western part of the nation. The slightly protruding forehead and long tail of these fish were prized in Taiwanese society as bringing luck in geomancy. A gourami in a community tank will snap and charge any other fish which are small enough for it to bully. Like most aquarium dwellers, giant gourami can be quickly raised with larger, more passive fish. However, if other fish are added to a tank, either large or small, they might be killed within a short period.
Sources: en.wikipedia.org
== Contraindications == The use of valsartan in pregnancy is avoided due to the potential risk of fetal toxicity. The U.S. Food and Drug Administration has a black box warning for valsartan/hydrochlorothiazide use during pregnancy. The use of hydrochlorothiazide is avoided in those with anuria or severe kidney disease.
=== Body wall === The body wall layers include a thin cuticle covering, an epidermis consisting of a single layer of cells, a thick dermis formed of connective tissue, a thin coelomic myoepithelial layer for the muscles, and a peritoneum which lines the body cavity. The dermis contains an endoskeleton of calcium carbonate components known as ossicles. These are honeycomb-like structures composed of calcite microcrystals arranged in a lattice. They vary in form, from flat plates to granules to spines, and cover the aboral (top) surface. Some are specialised structures such as the madreporite (the entrance to the water vascular system), pedicellariae, and paxillae. Paxillae are umbrella-like structures found on starfish that live buried in substrate. The edges of adjacent paxillae meet to form a false cuticle with a water cavity beneath in which the madreporite and delicate gill structures are protected. The ossicles are located under the epidermal layer, even those emerging externally. Several groups of starfish, including Valvatida and Forcipulatida, possess pedicellariae. These are scissor-like ossicles at the tip of the spine which displace organisms from resting on the starfish's surface. Some species like Labidiaster annulatus and Novodinia antillensis use their pedicellariae to catch prey. There may also be papulae, thin-walled protrusions of the body cavity that reach through the body wall into the surrounding water. These serve a respiratory function.
== History == Reduction of biomolecules with trialkyphosphines received little attention for decades because historically available phosphines were extremely malodorous and/or insoluble in water. In 1969, TCEP was reported as an odorless and water-soluble trialkyphosphine suitable for biochemical use, however the potential use of TCEP for biochemical applications was almost totally ignored for decades. In 1991, Burns reported a new convenient synthetic procedure for TCEP, which set off TCEP becoming more widely available and marketed as a "new" reducing agent for biochemical use, & thus TCEP came into more widespread use throughout the 1990s.
== Terminology == The term "carbohydrate" has many synonyms and the definition can depend on context. Terms associated with carbohydrate include "sugar", "saccharide", "glucan", and "glucide". In food science the term "carbohydrate" often means any food that is rich in starch (such as cereals, bread and pasta) or simple carbohydrates, or fairly simple sugars such as sucrose (found in candy, jams, and desserts). Carbohydrates can also refer to dietary fiber, like cellulose.
S + O2 → SO2 (sulfur dioxide) 2 SO2 + O2 → 2 SO3 (sulfur trioxide) Many other sulfur oxides are observed including the sulfur-rich oxides sulfur monoxide, disulfur monoxide, disulfur dioxides, and higher oxides containing peroxo groups.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.